GlassScriptPhysician profile
Kyle A Wilson
NPI 1841619905
$4,305.57
in general payments reported to CMS, 2019-2025
32 companies · $472 in 2025
The $472 reported for 2025 was more than what 79% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $577 · 2020: $749 · 2021: $972 · 2022: $552 · 2023: $720 · 2024: $263 · 2025: $472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,455.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,302.00 | 2019-2023 | Orilissa, Lo Loestrin Fe |
| Therapeuticsmd, INC. | $359.89 | 2019-2022 | |
| Exeltis, USA INC. | $244.02 | 2019-2025 | Tyblume, Slynd |
| Mayne Pharma Commercial LLC | $244.02 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $214.18 | 2023-2025 | Myfembree |
| Pfizer INC. | $204.72 | 2019-2025 | |
| Astellas Pharma US INC | $197.00 | 2023-2025 | Veozah, Myrbetriq |
| Evofem Biosciences, INC. | $185.95 | 2020-2022 | |
| Hologic Sales and Service, LLC | $133.47 | 2019-2025 | Fluent Fluid Management System, Myosure Tissue Removal Device, Aptima |
| Myovant Sciences INC. | $132.69 | 2021-2022 | |
| Agile Therapeutics, INC. | $125.42 | 2021-2023 | Twirla |
| Roche Diagnostics Corporation | $102.04 | 2019-2021 | |
| Coopersurgical, INC. | $100.00 | 2020 | |
| Organon LLC | $99.84 | 2024-2025 | Nexplanon |
| Dexcom, INC. | $97.30 | 2025 | Dexcom G6 Transmitter |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $93.20 | 2020-2021 | |
| Amag Pharmaceuticals, INC. | $78.84 | 2019-2021 | |
| Lupin INC. | $69.44 | 2019-2020 | |
| Millicent US INC | $68.34 | 2020-2023 | Intrarosa, Femring |
| Bayer Healthcare Pharmaceuticals INC. | $50.25 | 2019-2023 | |
| Tersera Therapeutics LLC | $25.16 | 2023 | Zoladex |
| Medtronic, INC. | $24.38 | 2023 | Truclear |
| Meditrina | $19.84 | 2025 | |
| Mission Pharmacal Company | $16.51 | 2020 | |
| Mallinckrodt Enterprises LLC | $16.27 | 2019 | |
| Mallinckrodt Hospital Products INC. | $15.54 | 2020 | |
| Mylan Pharmaceuticals INC. | $15.35 | 2021 | |
| Avion Pharmaceuticals | $14.73 | 2019 | |
| Ethicon US, LLC | $14.13 | 2025 | Stratafix |
| Amgen INC. | $14.08 | 2024 | Evenity, Prolia |
| Lilly USA, LLC | $13.58 | 2021 | |
| Exact Sciences Corporation | $13.39 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.